首页> Bulletin du cancer> Safety profile of immune checkpoint inhibitors according to cancer type.

Safety profile of immune checkpoint inhibitors according to cancer type.

导出 LinkOut

翻译打印收藏纠错

第一作者： Chloé,Guérin

第一单位： Grenoble Alpes University Hospital, Department of Internal Medicine/Clinical Immunology, Grenoble, France. Electronic address: cguerin2@chu-grenoble.fr.

作者： Chloé,Guérin ^[1] ; Mathieu,Laramas ^[2] ; François,Bettega ^[3] ; Alexis,Bocquet ^[4] ; Elodie,Berton ^[5] ; Maxime,Lugosi ^[6] ; Laurence,Bouillet ^[4] ; Anne-Claire,Toffart ^[5]

作者单位： Grenoble Alpes University Hospital, Department of Internal Medicine/Clinical Immunology, Grenoble, France. Electronic address: cguerin2@chu-grenoble.fr. ^[1] Grenoble Alpes University Hospital, Department of Oncology, Grenoble, France. ^[2] CHU Grenoble Alpes, University Grenoble Alpes, Inserm, HP2, Grenoble, France. ^[3] Grenoble Alpes University Hospital, Department of Internal Medicine/Clinical Immunology, Grenoble, France. ^[4] Grenoble Alpes University Hospital, Department of Thoracic Oncology, Grenoble, France. ^[5] Grenoble Alpes University Hospital, Department of Infectious Diseases, Grenoble, France. ^[6]

关键词 Cancer Effet indésirable immuno-médié Immune checkpoint inhibitors Immune-related adverse event Inhibiteur de checkpoint immunitaire

医学主题词人类(Humans);回顾性研究(Retrospective Studies);肿瘤(Neoplasms);自身免疫疾病(Autoimmune Diseases)

DOI 10.1016/j.bulcan.2023.04.011

PMID 37225616

发布时间 2023-06-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交